Experience

Celltrion Healthcare Canada Limited
• Canada
• Pharmaceutical Manufacturing
• 1 - 100 Employee
• MSL Manager

  • Jun 2022 - Present


Fresenius Kabi Canada

• Canada
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• MSL - Immune-inflammatory Diseases - Biosimilars

  • Sep 2020 - Jul 2022

  MSL for Quebec Ontario Therapeutic areas: - Inflammatory bowel diseases (CD, UC) - Rheumatology inflammatory conditions (RA, SpA, PsA) MSL for Quebec Ontario Therapeutic areas: - Inflammatory bowel diseases (CD, UC) - Rheumatology inflammatory conditions (RA, SpA, PsA)



Amgen

• United States
• Biotechnology Research
• 700 & Above Employee

• Senior MSL in Hemato-Oncology and Oncology

  • Jul 2017 - Dec 2019

  • TA and products covered: Multiple Myeloma (carfilzomib, anti-BCMA BiTE), Colorectal Cancer (Panitumumab; Bevacizumab biosimilar), Acute Lymphoid Leukemia (Blinatumomab), Breast Cancer (Denosumab, Trastuzumab-Biosimilar) and Prostate Cancer (Denosumab) • Successfully engaged KOLs in AdBoards and CME activities • Cross functional collaboration: as a reliable team player, provided constant support to Market Access and Marketing initiatives, Coordinated field activities with sales… Show more • TA and products covered: Multiple Myeloma (carfilzomib, anti-BCMA BiTE), Colorectal Cancer (Panitumumab; Bevacizumab biosimilar), Acute Lymphoid Leukemia (Blinatumomab), Breast Cancer (Denosumab, Trastuzumab-Biosimilar) and Prostate Cancer (Denosumab) • Successfully engaged KOLs in AdBoards and CME activities • Cross functional collaboration: as a reliable team player, provided constant support to Market Access and Marketing initiatives, Coordinated field activities with sales representatives Show less • TA and products covered: Multiple Myeloma (carfilzomib, anti-BCMA BiTE), Colorectal Cancer (Panitumumab; Bevacizumab biosimilar), Acute Lymphoid Leukemia (Blinatumomab), Breast Cancer (Denosumab, Trastuzumab-Biosimilar) and Prostate Cancer (Denosumab) • Successfully engaged KOLs in AdBoards and CME activities • Cross functional collaboration: as a reliable team player, provided constant support to Market Access and Marketing initiatives, Coordinated field activities with sales… Show more • TA and products covered: Multiple Myeloma (carfilzomib, anti-BCMA BiTE), Colorectal Cancer (Panitumumab; Bevacizumab biosimilar), Acute Lymphoid Leukemia (Blinatumomab), Breast Cancer (Denosumab, Trastuzumab-Biosimilar) and Prostate Cancer (Denosumab) • Successfully engaged KOLs in AdBoards and CME activities • Cross functional collaboration: as a reliable team player, provided constant support to Market Access and Marketing initiatives, Coordinated field activities with sales representatives Show less



Paladin Labs

• Canada
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Lead MSL, Oncology

  • Jul 2015 - Jul 2017

  • Regional and national roles in Hemato-Oncology; launched ponatinib in Canada for CML • Collaborated with Marketing, Market Access and MedInfo • Organized speaker tours across Canada with national and international speakers • Trained new MSLs, and manage medical field activities for appropriate interactions with KOLs • Elaborated national and regional strategy and plans for medical field activities • Elaborated medical material for field interactions and presentations •… Show more • Regional and national roles in Hemato-Oncology; launched ponatinib in Canada for CML • Collaborated with Marketing, Market Access and MedInfo • Organized speaker tours across Canada with national and international speakers • Trained new MSLs, and manage medical field activities for appropriate interactions with KOLs • Elaborated national and regional strategy and plans for medical field activities • Elaborated medical material for field interactions and presentations • Organized and led successful regional and national advisory boards with KOL experts in CML, ALL and Neuroblastoma • Organized and led investigator meetings for clinical trials in ph+ALL Show less • Regional and national roles in Hemato-Oncology; launched ponatinib in Canada for CML • Collaborated with Marketing, Market Access and MedInfo • Organized speaker tours across Canada with national and international speakers • Trained new MSLs, and manage medical field activities for appropriate interactions with KOLs • Elaborated national and regional strategy and plans for medical field activities • Elaborated medical material for field interactions and presentations •… Show more • Regional and national roles in Hemato-Oncology; launched ponatinib in Canada for CML • Collaborated with Marketing, Market Access and MedInfo • Organized speaker tours across Canada with national and international speakers • Trained new MSLs, and manage medical field activities for appropriate interactions with KOLs • Elaborated national and regional strategy and plans for medical field activities • Elaborated medical material for field interactions and presentations • Organized and led successful regional and national advisory boards with KOL experts in CML, ALL and Neuroblastoma • Organized and led investigator meetings for clinical trials in ph+ALL Show less



Bristol-Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Field Scientific Advisor - Oncology

  • Jan 2013 - Jul 2015

  • Covered the immune-oncology (IO) portfolio: Ipilimumab and Nivolumab for metastatic melanoma and lung cancer; Elotuzumab for multiple myeloma • Covered Dasatinib (CML/ph+ALL) and Cetuximab (colorectal cancer) field medical activities • Developed strong relationships with key investigators and opinion leaders in Quebec and Atlantics, maintained knowledge of their research and scientific interests • Did on site training presentations on Immuno-Oncology basics and principles… Show more • Covered the immune-oncology (IO) portfolio: Ipilimumab and Nivolumab for metastatic melanoma and lung cancer; Elotuzumab for multiple myeloma • Covered Dasatinib (CML/ph+ALL) and Cetuximab (colorectal cancer) field medical activities • Developed strong relationships with key investigators and opinion leaders in Quebec and Atlantics, maintained knowledge of their research and scientific interests • Did on site training presentations on Immuno-Oncology basics and principles, presentations of clinical data obtained in metastatic melanoma and lung cancer, and presentations for SIV in clinical study sites • Provided support to activities of Research Clinical Oncology, Market Access and Marketing groups • Trained new sales representative and KAMs on IO basics and IO products Show less • Covered the immune-oncology (IO) portfolio: Ipilimumab and Nivolumab for metastatic melanoma and lung cancer; Elotuzumab for multiple myeloma • Covered Dasatinib (CML/ph+ALL) and Cetuximab (colorectal cancer) field medical activities • Developed strong relationships with key investigators and opinion leaders in Quebec and Atlantics, maintained knowledge of their research and scientific interests • Did on site training presentations on Immuno-Oncology basics and principles… Show more • Covered the immune-oncology (IO) portfolio: Ipilimumab and Nivolumab for metastatic melanoma and lung cancer; Elotuzumab for multiple myeloma • Covered Dasatinib (CML/ph+ALL) and Cetuximab (colorectal cancer) field medical activities • Developed strong relationships with key investigators and opinion leaders in Quebec and Atlantics, maintained knowledge of their research and scientific interests • Did on site training presentations on Immuno-Oncology basics and principles, presentations of clinical data obtained in metastatic melanoma and lung cancer, and presentations for SIV in clinical study sites • Provided support to activities of Research Clinical Oncology, Market Access and Marketing groups • Trained new sales representative and KAMs on IO basics and IO products Show less


Research Center - Hospital Maisonneuve-Rosemont
• Director, Platform of Translational Research

  • Jan 2010 - Dec 2012


Theratechnologies

• Canada
• Biotechnology Research
• 100 - 200 Employee

• Contractual cell biologist

  • Jan 2009 - Jul 2009

  • Produced and amplified numerous cell clones expressing a luciferase gene as reporter to the activation of human growth hormone receptor when stimulated by proprietary specific peptides • Developed and troubleshooted the luciferase assay for future preclinical purposes of the company • Produced and amplified numerous cell clones expressing a luciferase gene as reporter to the activation of human growth hormone receptor when stimulated by proprietary specific peptides • Developed and troubleshooted the luciferase assay for future preclinical purposes of the company



Kiadis Pharma

• Netherlands
• Biotechnology
• 1 - 100 Employee

• Director of Translational Research

  • Oct 2007 - Dec 2008

  Kiadis Pharma, a private Holland-based company, acquired Celmed BioSciences in December 2006 and moved the Canadian headquarter to Holland, with products in clinical trials focused on oncology and immunology, including products for the treatment of blood cancers, the treatment of chronic GvHD, and the prevention of acute GvHD for making mismatched hematopoietic stem cell transplantation (HSCT) possible. Kiadis down sized Montreal site on November 2008 for economical reasons and closed it… Show more Kiadis Pharma, a private Holland-based company, acquired Celmed BioSciences in December 2006 and moved the Canadian headquarter to Holland, with products in clinical trials focused on oncology and immunology, including products for the treatment of blood cancers, the treatment of chronic GvHD, and the prevention of acute GvHD for making mismatched hematopoietic stem cell transplantation (HSCT) possible. Kiadis down sized Montreal site on November 2008 for economical reasons and closed it down on April 2009 Show less Kiadis Pharma, a private Holland-based company, acquired Celmed BioSciences in December 2006 and moved the Canadian headquarter to Holland, with products in clinical trials focused on oncology and immunology, including products for the treatment of blood cancers, the treatment of chronic GvHD, and the prevention of acute GvHD for making mismatched hematopoietic stem cell transplantation (HSCT) possible. Kiadis down sized Montreal site on November 2008 for economical reasons and closed it… Show more Kiadis Pharma, a private Holland-based company, acquired Celmed BioSciences in December 2006 and moved the Canadian headquarter to Holland, with products in clinical trials focused on oncology and immunology, including products for the treatment of blood cancers, the treatment of chronic GvHD, and the prevention of acute GvHD for making mismatched hematopoietic stem cell transplantation (HSCT) possible. Kiadis down sized Montreal site on November 2008 for economical reasons and closed it down on April 2009 Show less



Celmed Biosciences, Saint-Laurent, QC, Canada

• Scientific Director - Director of Preclinical Laboratories

  • Jul 2005 - Oct 2007

  • Responsible for all non-clinical activities in Canada, including preclinical development, clinical support for ongoing trials and training of technical personnel in clinical sites implementing Celmed’s processes and products. • Responsible for the development of preclinical work on Theralux™-based programs to support the filling of coming phase II clinical trials for several indications, achievement of commercially acceptable doses of the product for regulatory submissions and immediate… Show more • Responsible for all non-clinical activities in Canada, including preclinical development, clinical support for ongoing trials and training of technical personnel in clinical sites implementing Celmed’s processes and products. • Responsible for the development of preclinical work on Theralux™-based programs to support the filling of coming phase II clinical trials for several indications, achievement of commercially acceptable doses of the product for regulatory submissions and immediate use in the ongoing clinical trial. • Managed and supported the preclinical development at external sites for IND/CTA filling and application • Managed the outsourcing of specific studies to external CROs • Established the budget of all the preclinical research and clinical support activities • Developed a new semi-automated and closed cell processing system for cell therapy consistent with GLP guidelines

• Director, Research Laboratories

  • Dec 2003 - Jul 2005

  • Developed a new cellular therapy system called extracorporeal photochemotherapy and aimed to the treatment of patients with chronic GvHD, and successfully brought the project from the research-phase to an IND application in less than 12 months. IND was subsequently approved by both FDA and TPD, and clinical trials were initiated evaluating ECP for the treatment of patients with chronic graft-versus-host disease. • Developed, qualified and validated several specific bio-analytical assays by… Show more • Developed a new cellular therapy system called extracorporeal photochemotherapy and aimed to the treatment of patients with chronic GvHD, and successfully brought the project from the research-phase to an IND application in less than 12 months. IND was subsequently approved by both FDA and TPD, and clinical trials were initiated evaluating ECP for the treatment of patients with chronic graft-versus-host disease. • Developed, qualified and validated several specific bio-analytical assays by spectrofluorometry and flow-cytometry and T-cell proliferation assays, to measure effectiveness and safety of the immune-cell product • Developed and maintained scientific collaboration with principal investigators in the US and Canada to attract and retain their participation in clinical trials, to complete research work accepted for posters or oral presentations, and to support institutional review board approvals for clinical trials • Served as internal scientific reviewer and advisor for several external collaborations and due diligence efforts for acquisition and in-licensing candidates including NewBiotics, which Celmed acquired in 2005.

• Senior Scientist – Program Co-Director

  • Aug 2002 - Dec 2003

  • Led a team responsible for the development of in-house methods for isolation, amplification, differentiation and identification of human neural stem cells, and their transfer to Celmed’s clinical laboratory in Los Angeles • Promoted with additional responsibilities for the Los Angeles laboratory shortly before the LA lab was spun out of Celmed.


Celmed BioSciences
• Biotechnology Research
• Director R&D

  • 2004 - 2006


University of Montreal - Laboratory of Immunology (R.P. Sekaly)

• Research Associate

  • Jul 2000 - Jul 2002

  • Designed experimental protocols, and supervised the progress of research projects • Trained students for diverse techniques such as culture of primary human lymphocytes, protein extraction and dosage, western blotting, radiolabelling of cellular proteins, immunoprecipitation, pull-down assays, and immunocytochemistry. • Designed experimental protocols, and supervised the progress of research projects • Trained students for diverse techniques such as culture of primary human lymphocytes, protein extraction and dosage, western blotting, radiolabelling of cellular proteins, immunoprecipitation, pull-down assays, and immunocytochemistry.



CEA-CENG-INSERM, Grenoble, France

• Post-Doctoral Fellow, Laboratory of Calcium Signaling

  • Feb 1998 - Oct 1999

  Developed expression plasmids and cell lines for wild-type and mutant genes encoding the signaling protein Triadin, present in the Rhyanodine receptor involved in the regulation of cellular calcium homeostasis. Developed expression plasmids and cell lines for wild-type and mutant genes encoding the signaling protein Triadin, present in the Rhyanodine receptor involved in the regulation of cellular calcium homeostasis.

• Post-Doctoral Fellow, Unit of Cell Signaling

  • Oct 1995 - Oct 1997

  • Studied the regulation of the anti-tumor protein p53 through the activation of its antiproliferative and proapoptotic functions via calcium signalling (calcium-binding protein S100B, PKC isoforms), in response to g-irradiation, UV-irradiation, cisplatin, and doxorubicin. • Engineered human cell lines expressing the protein S100B involved in calcium signal. • Designed and performed experiments as various as transfection, radio-labelling of cell proteins, immunoprecipitations… Show more • Studied the regulation of the anti-tumor protein p53 through the activation of its antiproliferative and proapoptotic functions via calcium signalling (calcium-binding protein S100B, PKC isoforms), in response to g-irradiation, UV-irradiation, cisplatin, and doxorubicin. • Engineered human cell lines expressing the protein S100B involved in calcium signal. • Designed and performed experiments as various as transfection, radio-labelling of cell proteins, immunoprecipitations, western-blotting, northern-blotting, immuno-fluorescence, analysis of cell cycle parameters by FACS Show less • Studied the regulation of the anti-tumor protein p53 through the activation of its antiproliferative and proapoptotic functions via calcium signalling (calcium-binding protein S100B, PKC isoforms), in response to g-irradiation, UV-irradiation, cisplatin, and doxorubicin. • Engineered human cell lines expressing the protein S100B involved in calcium signal. • Designed and performed experiments as various as transfection, radio-labelling of cell proteins, immunoprecipitations… Show more • Studied the regulation of the anti-tumor protein p53 through the activation of its antiproliferative and proapoptotic functions via calcium signalling (calcium-binding protein S100B, PKC isoforms), in response to g-irradiation, UV-irradiation, cisplatin, and doxorubicin. • Engineered human cell lines expressing the protein S100B involved in calcium signal. • Designed and performed experiments as various as transfection, radio-labelling of cell proteins, immunoprecipitations, western-blotting, northern-blotting, immuno-fluorescence, analysis of cell cycle parameters by FACS Show less